

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

IN RE:

LORAZEPAM and CLORAZEPATE
ANTITRUST LITIGATION

This Document Relates to:

THE STATE OF CONNECTICUT, et al.,

Plaintiff,

v.

MYLAN LABORATORIES, INC.,
CAMBEX CORP., PROFARMACO S.R.L.,
GYMA LABORATORIES OF AMERICA, INC.,
and SST CORPORATION,

Defendants.

MDL No. 1290 (TFH)

Civ. No. 1:98 CV 03115 (TFH)

FILED

FEB - 1 2002

NANCY MAYER WHITTINGTON, CLERK
U.S. DISTRICT COURT

ORDER

This action (the "Action") having come before this Court for a hearing on November 29, 2001, pursuant to the Order of this Court dated April 27, 2001 (the "Preliminary Approval Order") to consider and determine the matters set forth in the Preliminary Approval Order; and due notice of the hearing having been published; and all persons having objections been provided the opportunity to object to the proposed settlements in this Action set forth in the:

(i) Settlement Agreement between the Plaintiff States, the Federal Trade Commission (the "FTC"), Mylan Laboratories, Inc. ("Mylan"), Gyma Laboratories of America, Inc. ("Gyma"), Profarmaco S.r.l. ("Profarmaco"), and Cambrex Corporation ("Cambrex"); and (ii) Settlement Agreement between the Plaintiff States and SST Corporation ("SST") (the "Settlements"); and

the Court having considered the matters, including all papers filed in connection therewith and oral presentations of counsel at the hearing; and the Court having granted final approval of the Settlements; and

The Court having granted the motion of the Intervenor by Order dated April 27, 2001; and the Court having considered the Stipulation of Settlement and Dismissal entered into between the Intervenor, Mylan, Cambrex, Profarmaco and Gyma (the "Stipulation") in which Mylan Pharmaceuticals, Inc. agreed to pay the sum of up to \$4 million as attorneys fees to Indirect Purchaser Lead Counsel (as defined in the Stipulation) on behalf of Indirect Purchaser Counsel (as defined in the Stipulation) in respect to performance as more fully set forth in the Stipulation; and the Court having considered the matter, including all papers filed in connection therewith, and the oral presentations of counsel at the hearing, and good cause appearing therefor,

IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:

1. The Court has jurisdiction over the subject matter of this Action and over all of the parties to the Stipulation.
2. The Intervenor are hereby directed to take the steps necessary to dismiss the cases, which they filed as set forth in the Schedule annexed as Exhibit 1.
3. The Court finds that the Intervenor's counsel, and other counsel for the indirect purchaser plaintiffs in the actions which are the subject to this Court's Order of March 9, 2000 (the "Related Actions") have assisted in prosecuting, inter alia, the State Purchaser Actions, and the parties to this Action having no objection, it is hereby ordered that, pursuant to the Stipulation, Mylan Pharmaceuticals, Inc. pay the sum of \$ 4 million to Indirect Purchaser Lead Counsel (as defined in the Stipulation) on behalf of Indirect Purchaser

TF

Counsel (as defined in the Stipulation) as attorneys' fees in the manner set forth in the Stipulation; and

4. Without in any way affecting the finality of this Order, this Court hereby retains jurisdiction over the parties to the Stipulation for the purpose of implementing and enforcing the terms of the Stipulation, as well as all matters relating to the terms of this Order.

SO ORDERED this 1st day of February 2002.



Hon. Thomas F. Hogan
United States District Judge

EXHIBIT 1

SCHEDULE OF ACTIONS

<u>Jurisdiction</u>	<u>Title of Action</u>
Alabama: Circuit Court of Jefferson County	<i>Ashcraft v. Mylan Laboratories, Inc., et al.</i> , No. CV99-39 (the "Ashcraft Action");
Arizona: Superior Court of Yavapai County	<i>McLaughlin v. Mylan Laboratories, Inc., et al.</i> , No. CV980863 (the "McLaughlin Action");
California: Superior Court of San Francisco County	<i>Mylan Generic Drug Antitrust Consumer Cases</i> , Judicial Counsel Coordination Proceeding No. 4075 (the "California Action");
District of Columbia: Superior Court	<i>Datlow v. Mylan Laboratories, Inc., et al.</i> , No. 0000266-99 (the "Datlow Action");
Florida: Circuit Court of Broward County	<i>Dearman v. Mylan Laboratories, Inc., et al.</i> , No. 99-000123 (the "Dearman Action");
Kansas: District Court of Sedgwick County	<i>Millender v. Mylan Laboratories, Inc., et al.</i> , No. 00C1708 (the "Millender Action");
Massachusetts: Superior Court of Hampden County	<i>Brockney v. Mylan Laboratories, Inc., et al.</i> , No. 00-479 (the "Brockney Action");
Michigan: Circuit Court of Oakland County	<i>Dunkel v. Mylan Laboratories, Inc., et al.</i> , No. 98-001503-CZ (the "Dunkel Action");
Minnesota: District Court of Hennepin County	<i>Pettit v. Mylan Laboratories, Inc., et al.</i> , No. MC-00-002501 (the "Pettit Action");

New Jersey:
Superior Court of
Bergen County

Kieffer v. Mylan Laboratories, Inc. et al., No. BER-L-365-99EM
(the "Kieffer Action");

New York:
Supreme Court of
New York County

Migden v. Mylan Laboratories, Inc., et al., No. 99-600120 (the
"Migden Action");

North Carolina:
Superior Court of
Carteret County

Swain v. Mylan Laboratories, Inc., et al., No. 99CVS235 (the
"Swain Action");

Tennessee:
Chancery Court of
Sumner County

Wright v. Mylan Laboratories, Inc., et al., No. 99C37 (the
"Wright Action"); and

Wisconsin:
Circuit Court of
Dane County

*Scenic Bluffs Community Health Center v. Mylan Laboratories,
Inc., et al.*, No. 98CV3286 (the "Scenic Bluffs Action").